2013
DOI: 10.5005/jp-journals-10028-1054
|View full text |Cite
|
Sign up to set email alerts
|

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Abstract: This article deals primarily with the selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and evaluated, and those that warrant future investigations. Various scientific and practical issues related to the production and availability of these radionuclides is briefly addressed. At brookhaven national laboratory (BNL), we have developed a paradigm that involves specific individual 'dua… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
16
0

Year Published

2015
2015
2019
2019

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(16 citation statements)
references
References 43 publications
(58 reference statements)
0
16
0
Order By: Relevance
“…However, owing to the poor crosssection of both these reactions and the need for a very high flux reactor and highly enriched targets that are essential to produce sufficient quantities of 117m Sn, large-scale production of this radionuclide is not practical. Moreover, the low specific activity of the produced 117m Sn can be a limiting factor for radiolabelling of target compounds (Srivastava, 2013). Additional accelerator based production routes have been investigated to produce no carrier added (nca) 117m Sn, using 3 He particle-induced reactions on 116 Cd and 115 In (Maslov et al, 2011;Srivastava, 2013).…”
Section: Iid Tin-117mmentioning
confidence: 99%
See 1 more Smart Citation
“…However, owing to the poor crosssection of both these reactions and the need for a very high flux reactor and highly enriched targets that are essential to produce sufficient quantities of 117m Sn, large-scale production of this radionuclide is not practical. Moreover, the low specific activity of the produced 117m Sn can be a limiting factor for radiolabelling of target compounds (Srivastava, 2013). Additional accelerator based production routes have been investigated to produce no carrier added (nca) 117m Sn, using 3 He particle-induced reactions on 116 Cd and 115 In (Maslov et al, 2011;Srivastava, 2013).…”
Section: Iid Tin-117mmentioning
confidence: 99%
“…Moreover, the low specific activity of the produced 117m Sn can be a limiting factor for radiolabelling of target compounds (Srivastava, 2013). Additional accelerator based production routes have been investigated to produce no carrier added (nca) 117m Sn, using 3 He particle-induced reactions on 116 Cd and 115 In (Maslov et al, 2011;Srivastava, 2013). However, these reactions could provide only low yield.…”
Section: Iid Tin-117mmentioning
confidence: 99%
“…Among the scandium isotopes, Sc-47 (β − emitter) is well suited for use in targeted radionuclide therapy. There is then a potential interest to use Sc-44 for dosimetry studies before using Sc-47 for therapy, as a theranostic approach ( 6 ).…”
Section: Deuteron Production Of Non-conventional Radionuclidesmentioning
confidence: 99%
“…188 Re: T 1/2 = 17.004 h, E β-mean = 763 keV with 99m Tc: T 1/2 = 6.0072 h, E γ = 140.511 keV [9]). Theranostics provides a personalized medicine approach allowing the selection of patients that will benefit from the particular treatment, also avoiding unnecessary and expensive therapies [8,10,11,12].…”
Section: Introductionmentioning
confidence: 99%